Bimatoprost and Travoprost

Eisenberg, Dan; Toris, Carol B.; Camras, Carl B.

doi:10.1016/s0039-6257(02)00327-2

Cited by 99 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While latanoprost and travoprost are ester prodrugs and analogues of prostaglandin (PG) F 2 α , bimatoprost is regarded as a prostamide, and debate continues as to whether it is an amide prodrug [3,4,5]. The exact mechanism of action of PG analogues is not entirely clear.…”

Section: Introductionmentioning

confidence: 99%

“…The exact mechanism of action of PG analogues is not entirely clear. The free acids of latanoprost, travoprost and bimatoprost all fully and selectively activate the FP receptor relative to the naturally occurring agonist of PGF 2 α , although with variable receptor affinity [3,4,5,6]. …”

Section: Introductionmentioning

confidence: 99%

“…While a higher IOP-lowering effect for bimatoprost compared to other ocular hypotensive agents has been suggested, generally these agents provide a similar degree of IOP lowering [4,7,8] without changing the rate of aqueous humour production while increasing its outflow [1,2,3,4,5]. Once daily administration and near absence of systemic side effects enhance tolerability of and compliance to these agents [6].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues

Vural¹,

Torun-Acar²,

Acar³

2011

Ophthalmologica

View full text Add to dashboard Cite

Background/Aims: While topical ocular hypotensive agents cause secretion of endogenous prostaglandin (PG), systemic and topical non-steroidal anti-inflammatory agents inhibit its production; thus, they may interfere with therapeutic efficacy. This study aimed to investigate the effect of add-on treatment with ketorolac on intra-ocular pressure (IOP)-lowering effects of three different PG analogues. Methods: This study included 30 adult bilateral glaucoma patients who had been receiving PG analogues for primary open-angle glaucoma (n = 25) or pseudoexfoliation glaucoma (n = 5). Ketorolac tromethamine 0.5% and placebo drops were administered to the right and left eyes of the patients, respectively, 4 times a day for 1 week. IOP measurements were performed at baseline, within the first 4 h after application, on days 1, 3 and 7, and 1 and 7 days after discontinuation of the treatment. Results: Eyes receiving ketorolac had significantly lower IOP throughout the treatment period (p < 0.001). Patients who were on latanoprost, travoprost and bimatoprost did not differ with regard to the change in IOP (p = 0.780). After discontinuation, pressures became similar on day 1 (p = 0.796) and day 7 (p = 0.314). Conclusion: In glaucoma patients, ketorolac significantly enhances the IOP-lowering effects of latanoprost, travoprost and bimatoprost.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues

Vural¹,

Torun-Acar²,

Acar³

2011

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Among this group of drugs, bimatoprost (Lumigan; Allergan, Irvine, Calif., USA) and travoprost (Travatan; Alcon, Fort Worth, Tex., USA) are two newer widely used intraocular-pressure-lowering agents in patients with glaucoma and ocular hypertension [22, 23]. Side effects associated with this group of drugs are reported as ocular hyperemia, increase in the length and thickness of the eyelashes, eyelid skin darkening, change in iris pigmentation, anterior uveitis and cystoid macular edema [21,24,25,26].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Alagöz

Bayer²,

Boran³

et al. 2008

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the subjective symptoms, conjunctival hyperemia, tearing response and conjunctival cytological changes secondary to topical administration of bimatoprost and travoprost for 6 months. Methods: Newly diagnosed primary open-angle glaucoma patients were randomly prescribed bimatoprost (35 cases) or travoprost (42 cases). Two patients in each group were excluded because they did not appear at their appointments regularly. Thus, 33 and 40 patients completed the study in the bimatoprost and travoprost groups, respectively. Redness, itching, foreign-body sensation, pain and discomfort were assessed by a questionnaire, and patients were examined for conjunctival hyperemia. Schirmer’s I and break-up time tests were performed, and impression cytology of conjunctiva was evaluated. Results: Subjective symptoms were similar in both groups. The only subjective symptom that changed significantly was redness. The change in conjunctival hyperemia along the study period correlated with the patient-reported redness in both groups, being highest on day 30. Schirmer’s test I and break-up time did not change with time and were similar in both groups. The impression cytology grade increased with time in both groups with the only significant difference between groups on day 90 (higher in the bimatoprost group). Conclusion: We observed conjunctival hyperemia as the most common side effect of bimatoprost and travoprost. Tear film functions were not affected by these drugs while cytological alterations were.

show abstract

“…Several studies have reported its incidence to be the highest in bimatoprost 0.03% compared to other prostaglandin analogs 43,44. However, the hyperemia is typically mild, transient and infrequently cited as a cause of drop discontinuation, which was seen in 3% 17. In one study, hyperemia peaked 1 day after commencing bimatoprost, and severity progressively declined at each visit during the 6-week study 45.…”

Section: Common Side Effectsmentioning

confidence: 97%

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

Lee

Mantravadi

Myers

2017

OPTH

View full text Add to dashboard Cite

Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the development and the progression of all forms of glaucoma. Bimatoprost 0.03% ophthalmic solution, introduced in 2001, is a synthetic prostamide with the unique mechanism of improving both uveoscleral and trabecular outflow. Comparative studies with other pharmacotherapies have shown favorable results for bimatoprost as a potent ocular hypotensive agent that is generally well tolerated. Common side effects include conjunctival hyperemia, eyelash growth, iris pigmentation and periorbital changes. Hyperemia rates were reduced following the introduction of bimatoprost 0.01%. Bimatoprost should be used with caution in those with higher risk of developing ocular inflammation and macular edema. However, the perceived risk of bimatoprost in these patient populations is likely greater than the actual risk observed in practice. Bimatoprost is currently in the center of several clinical trials including its use for dermatologic applications and sustained-release therapies for the treatment of ocular hypertension and glaucoma.

show abstract

Bimatoprost and Travoprost

Cited by 99 publications

References 45 publications

Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues

Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

Contact Info

Product

Resources

About